Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelicapavir (EDP-938) in Pediatric RSV
NCT04816721Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing Zelicapavir with Placebo (2 arms). Primary endpoints: Concentrations of EDP-938 in Plasma at Day 5, Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) and 1 more. Started Apr 2022; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04816721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816721.